Buprenorphine or Methadone Treatment
PreclinicalSmall molecule
Buprenorphine or Methadone Treatment is one of 37 small molecule programs targeting Opioid Use Disorder. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
36
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
116 competitors in Opioid Use Disorder
#DrugCompanyPhaseTrials
1Revia
TevaPhase 3
Belsomra
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Epidiolex
Jazz PharmaceuticalsPhase 2
Dayvigo
EisaiPhase 2
Ozempic
Novo NordiskPhase 2
Vraylar
AbbViePhase 2
Mounjaro
Eli LillyPhase 2
Victoza
Novo NordiskPhase 2
Diamox
TevaPhase 2
Buprenorphine/naloxone
AstellasPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- IIndiana University